Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
IRWD closed down 0.45 percent on Friday, March 16, 2018, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
|Weak or Absent||Down||Up||Up|
|See historical IRWD trend table...|
|Date||Alert Name||Type||% Chg|
|Mar 16||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup||0.00%|
|Mar 16||Wide Bands||Range Expansion||0.00%|
|Mar 16||Overbought Stochastic||Strength||0.00%|
|Mar 15||Bearish Engulfing||Bearish||-0.45%|
|Mar 15||Stochastic Sell Signal||Bearish||-0.45%|
|Mar 15||Outside Day||Range Expansion||-0.45%|
|Mar 15||Wide Bands||Range Expansion||-0.45%|
|Mar 15||Overbought Stochastic||Strength||-0.45%|
|Mar 14||Narrow Range Bar||Range Contraction||-1.22%|
|Mar 14||NR7||Range Contraction||-1.22%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more IRWD news...
|52 Week High||19.94|
|52 Week Low||12.89|
|200-Day Moving Average||15.9525|
|50-Day Moving Average||14.8008|
|20-Day Moving Average||14.872|
|10-Day Moving Average||15.072|
|Average True Range||0.5436|
|Chandelier Exit (Long, 3 ATRs )||14.4992|
|Chandelier Exit (Short, 3 ATRs )||15.4408|
|Upper Bollinger Band||15.8409|
|Lower Bollinger Band||13.9031|
|Percent B (%b)||0.75|
|MACD Signal Line||0.0852|
|Market Cap||2.3 Billion|
|Num Shares||150 Million|
|Price-to-Earnings (P/E) Ratio||-15.67|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||16.00|
|Resistance 3 (R3)||16.02||15.83||15.89|
|Resistance 2 (R2)||15.83||15.66||15.82||15.86|
|Resistance 1 (R1)||15.59||15.56||15.50||15.57||15.82|
|Support 1 (S1)||15.17||15.24||15.07||15.15||14.90|
|Support 2 (S2)||14.98||15.14||14.97||14.86|
|Support 3 (S3)||14.74||14.98||14.83|
|Support 4 (S4)||14.72|